

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/511537	First Named Inventor: Hanson
371 Filing Date: October 15, 2004	Attorney Docket No.: 100647-1P US
Examiner: Mark L. Berch	Group Art Unit : 1624
Customer No.: 22466	Confirmation No.: 4417
Title: Thioxanthine Derivatives as Myeloperoxidase Inhibitors	

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the cited foreign patent documents, non-patent publications, English language translation for any cited non-English language foreign non-patent publication, English language abstract(s) for an cited non-English language patent(s)/patent application publication(s), and cited International Search Report(s) are submitted herewith.

Applicants wish to note that: a) US Patent No. 7,108,997 cited in the accompanying SB08 form is the U.S. counterpart of WO0185146, which was cited by Applicants in the Information Disclosure Statement mailed October 15, 2004, and b) U.S Patent No. 4,820,709 cited in the accompanying SB08 form is the U.S. counterpart of CN Patent No.1013676 also cited in the accompanying SB08 form.

Applicants recognize that foreign search reports are not typically published on the face of an issued patent, and as a result Examiners typically draw a line through cited foreign search report(s). Unless notified to the contrary, however, Applicants shall conclude that any lined

through search report was in fact considered by the Examiner and lined through only for reasons related to the publication of the issued patent.

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☒ (2) after the period defined in (1) but before the mailing date of a **final Action** or a **Notice of Allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☒ the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. 26-0166, referencing Attorney Docket No. 100647-1P US, or
- ☐ (3) after the mailing date of a **final Action** or **Notice of Allowance** but before the payment of the **Issue Fee, AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. \_\_\_\_\_, referencing Attorney Docket No. \_\_\_\_\_, or

It is respectfully requested that each of the patents and publications listed on the attached Forms SB08, and other information contained herein, be considered by the Examiner and made of record in this application.

Respectfully submitted,  
/Jacqueline M. Cohen/

---

Name: Jacqueline M. Cohen  
Dated: 7/23/2007  
Reg. No.: 51,574  
Phone No.: 302-885-4269